Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Mair, X. Yang, L. Long, K. White, M. Nilsen, N. Morrell, M. R. MacLean (Glasgow, Cambridge, United Kingdom). Smad1 deficiency and female gender contribute to the development of pulmonary hypertension. Eur Respir J 2014; 44: Suppl. 58, 2946

Member's Comments

No comment yet.

Related content which might interest you: Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Molecular study of genetic modifiers in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Would RDW be a prognostic factor in pulmonary arterial hypertension? Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Long-term screening for pulmonary hypertension after pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014